In following in vitro experiments, heterogeneously originated CAFs from breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinomas, were tested to be sensitive to cell death by hFAP-CAR T cells in vitro, broadening our FAP-CAR T cells use. This evidence concerns the gene FAP and hepatocellular carcinoma.